6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

@article{Issaeva20106thioguanineSK,
  title={6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.},
  author={Natalia Issaeva and Huw D. Thomas and Tatjana Djureinovic and Janneke E. Jaspers and Ivaylo Stoimenov and Suzanne Kyle and Nicholas M Pedley and Ponnari Gottipati and Rafal Zur and Kate M Sleeth and Vicky Chatzakos and Evan A. Mulligan and Cecilia Lundin and Evgenia Gubanova and Ariena Kersbergen and Adrian L. Harris and Ricky A. Sharma and Sven Rottenberg and Nicola J Curtin and Thomas Helleday},
  journal={Cancer research},
  year={2010},
  volume={70 15},
  pages={6268-76}
}
Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively kill BRCA2-defective cells, we identified 6-thioguanine (6TG), which induces DNA double-strand breaks (DSB) that are repaired by HR. Furthermore, we show that 6TG is as efficient as a PARP inhibitor… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Drug therapy for hereditary cancers

Hereditary cancer in clinical practice • 2011
View 6 Excerpts
Highly Influenced

Reverse the Resistance to PARP Inhibitors

International journal of biological sciences • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Defining the roles of Cancer Res

IU De Silva, PJ McHugh, PH Clingen, JA. Hartley
Mol Cell Biol • 2010
View 1 Excerpt

Hydroxyureastalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair

PetermannE, OrtaML, IssaevaN, SchultzN, T Helleday
Mol Cell 2010;37:492–502 • 2010
View 1 Excerpt

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Proceedings of the National Academy of Sciences of the United States of America • 2008
View 5 Excerpts

Similar Papers

Loading similar papers…